Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in children
| Autor: | Y. V. Skvortsova, D. N. Balashov, V. M. Delyagin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.drug_class
reaction chemical and pharmacologic phenomena лечение Monoclonal antibody Mycophenolate Mycophenolic acid 03 medical and health sciences 0302 clinical medicine immune system diseases клиника Extracorporeal Photopheresis graft-versus-host disease medicine clinical pattern treatment business.industry pathogenesis трансплантация гемопоэтических стволовых клеток General Medicine medicine.disease transplantation of hematopoietic stem cells Tacrolimus surgical procedures operative Graft-versus-host disease 030220 oncology & carcinogenesis Sirolimus Immunology патогенез Medicine Methotrexate business реакция трансплантат против хозяина 030215 immunology medicine.drug |
| Zdroj: | Медицинский совет, Vol 1, Iss 1, Pp 136-139 (2016) |
| ISSN: | 2658-5790 2079-701X |
| Popis: | Up to 60 thousand hematopoietic stem cell transplantations (HSCT) are carried out globally all over the world. The outcome of HSCT is largely determined by the probability and severity of the graft-versus-host reaction/disease (GVHD). Treatment involves corticosteroids. Antithymocyte globulin, extracorporeal photopheresis, monoclonal antibodies to interleukins or their receptors, methotrexate, cyclosporine, tacrolimus, sirolimus, antithymocyte globulin, etc. are used in steroid-refractory GVHD. It is worth to mention that mycophenolate mofetil, esther of mycophenolic acid, blocks proliferation of T and B lymphocytes. In patients who are refractory to corticosteroids, the use of mycophenolate mofetil in isolation or in combination with cyclosporine, tacrolimus seems to be justified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|